New syringe design tested for eye disease treatment

NCT ID NCT07214740

Completed Disease control Sponsor: Apellis Pharmaceuticals, Inc. Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 24, 2026 · Updated 31 times

Summary

This study tested the safety of a drug called pegcetacoplan given through a prefilled syringe for people with geographic atrophy, a form of age-related macular degeneration that causes vision loss. 44 adults aged 60 and older received the injection in one eye. The goal was to see if the new syringe is safe and easy for doctors to use.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Austin Retina Associates

Austin, Texas, 78705, United States
California Retina Consultants

Bakersfield, California, 93309, United States
California Retina Consultants

Oxnard, California, 93036, United States
Retina Consultants of Texas

Katy, Texas, 77494, United States
Retina Consultants of Texas

Woodland, Texas, 77384, United States

Conditions

Explore the condition pages connected to this study.

GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION